166 related articles for article (PubMed ID: 38473290)
21. Postoperative circulating tumour DNA is associated with pathologic response and recurrence-free survival after resection of colorectal cancer liver metastases.
Bolhuis K; van 't Erve I; Mijnals C; Delis-Van Diemen PM; Huiskens J; Komurcu A; Lopez-Yurda M; van den Broek D; Swijnenburg RJ; Meijer GA; Punt CJA; Fijneman RJA
EBioMedicine; 2021 Aug; 70():103498. PubMed ID: 34333237
[TBL] [Abstract][Full Text] [Related]
22. Circulating Tumour DNA as Biomarker for Colorectal Liver Metastases: A Systematic Review and Meta-Analysis.
Wullaert L; van Rees JM; Martens JWM; Verheul HMW; Grünhagen DJ; Wilting SM; Verhoef C
Cells; 2023 Oct; 12(21):. PubMed ID: 37947598
[TBL] [Abstract][Full Text] [Related]
23. Perioperative Circulating Tumor DNA in Colorectal Liver Metastases: Concordance with Metastatic Tissue and Predictive Value for Tumor Burden and Prognosis.
He Y; Ma X; Chen K; Liu F; Cai S; Han-Zhang H; Hou T; Xiang J; Peng J
Cancer Manag Res; 2020; 12():1621-1630. PubMed ID: 32184665
[TBL] [Abstract][Full Text] [Related]
24. Serial circulating tumor DNA to predict early recurrence in patients with hepatocellular carcinoma: a prospective study.
Zhu GQ; Liu WR; Tang Z; Qu WF; Fang Y; Jiang XF; Song SS; Wang H; Tao CY; Zhou PY; Huang R; Gao J; Sun HX; Ding ZB; Peng YF; Dai Z; Zhou J; Fan J; Shi YH
Mol Oncol; 2022 Jan; 16(2):549-561. PubMed ID: 34543520
[TBL] [Abstract][Full Text] [Related]
25. Circulating Tumor DNA Analysis for Liver Cancers and Its Usefulness as a Liquid Biopsy.
Ono A; Fujimoto A; Yamamoto Y; Akamatsu S; Hiraga N; Imamura M; Kawaoka T; Tsuge M; Abe H; Hayes CN; Miki D; Furuta M; Tsunoda T; Miyano S; Kubo M; Aikata H; Ochi H; Kawakami YI; Arihiro K; Ohdan H; Nakagawa H; Chayama K
Cell Mol Gastroenterol Hepatol; 2015 Sep; 1(5):516-534. PubMed ID: 28210698
[TBL] [Abstract][Full Text] [Related]
26. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.
Yang M; Tan W; Yang X; Zhuo J; Lin Z; Cen B; Lian Z; Li H; Lu D; Wei X; Zheng S; Xu X
Cancer Biomark; 2020; 29(2):197-206. PubMed ID: 32623388
[TBL] [Abstract][Full Text] [Related]
27. Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer.
Lee B; Lipton L; Cohen J; Tie J; Javed AA; Li L; Goldstein D; Burge M; Cooray P; Nagrial A; Tebbutt NC; Thomson B; Nikfarjam M; Harris M; Haydon A; Lawrence B; Tai DWM; Simons K; Lennon AM; Wolfgang CL; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
Ann Oncol; 2019 Sep; 30(9):1472-1478. PubMed ID: 31250894
[TBL] [Abstract][Full Text] [Related]
28. Multi-Center Analysis of Liver Transplantation for Combined Hepatocellular Carcinoma-Cholangiocarcinoma Liver Tumors.
Dageforde LA; Vachharajani N; Tabrizian P; Agopian V; Halazun K; Maynard E; Croome K; Nagorney D; Hong JC; Lee D; Ferrone C; Baker E; Jarnagin W; Hemming A; Schnickel G; Kimura S; Busuttil R; Lindemann J; Florman S; Holzner ML; Srouji R; Najjar M; Yohanathan L; Cheng J; Amin H; Rickert CA; Yang JD; Kim J; Pasko J; Chapman WC; Majella Doyle MB
J Am Coll Surg; 2021 Apr; 232(4):361-371. PubMed ID: 33316425
[TBL] [Abstract][Full Text] [Related]
29. Significance of postoperative follow-up of patients with metastatic colorectal cancer using circulating tumor DNA.
Benešová L; Hálková T; Ptáčková R; Semyakina A; Menclová K; Pudil J; Ryska M; Levý M; Šimša J; Pazdírek F; Hoch J; Blaha M; Minárik M
World J Gastroenterol; 2019 Dec; 25(48):6939-6948. PubMed ID: 31908397
[TBL] [Abstract][Full Text] [Related]
30. Recurrence Prediction by Circulating Tumor DNA in the Patient with Colorectal Liver Metastases After Hepatectomy: A Prospective Biomarker Study.
Liu W; Jin KM; Zhang MH; Bao Q; Liu M; Xu D; Wang K; Xing BC
Ann Surg Oncol; 2023 Aug; 30(8):4916-4926. PubMed ID: 37219651
[TBL] [Abstract][Full Text] [Related]
31. Circulating tumor DNA as an emerging liquid biopsy biomarker for early diagnosis and therapeutic monitoring in hepatocellular carcinoma.
Wu X; Li J; Gassa A; Buchner D; Alakus H; Dong Q; Ren N; Liu M; Odenthal M; Stippel D; Bruns C; Zhao Y; Wahba R
Int J Biol Sci; 2020; 16(9):1551-1562. PubMed ID: 32226301
[TBL] [Abstract][Full Text] [Related]
32. Serial circulating tumor DNA profiling predicts tumor recurrence after liver transplantation for liver cancer.
Huang A; Guo DZ; Zhang X; Sun Y; Zhang SY; Zhang X; Fu XT; Wang YP; Yang GH; Sun QM; He YF; Song K; Huang XW; Yang XR; Liu WR; Ding ZB; Shi YH; Fan J; Zhou J
Hepatol Int; 2024 Feb; 18(1):254-264. PubMed ID: 37980313
[TBL] [Abstract][Full Text] [Related]
33. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
[TBL] [Abstract][Full Text] [Related]
34. Successful liver transplantation with ctDNA clearance after PD‑1 inhibitor plus FOLFOX‑HAIC treatment in HCC: A case report.
Zhao Y; Chen D; Yang B; Xu J; Wang L; Huang G; Wei L; Chen Z
Oncol Lett; 2024 Feb; 27(2):51. PubMed ID: 38192664
[TBL] [Abstract][Full Text] [Related]
35. Relationship between post-surgery detection of methylated circulating tumor DNA with risk of residual disease and recurrence-free survival.
Murray DH; Symonds EL; Young GP; Byrne S; Rabbitt P; Roy A; Cornthwaite K; Karapetis CS; Pedersen SK
J Cancer Res Clin Oncol; 2018 Sep; 144(9):1741-1750. PubMed ID: 29992492
[TBL] [Abstract][Full Text] [Related]
36. Unraveling the potential clinical utility of circulating tumor DNA detection in colorectal cancer-evaluation in a nationwide Danish cohort.
Henriksen TV; Demuth C; Frydendahl A; Nors J; Nesic M; Rasmussen MH; Reinert T; Larsen OH; Jaensch C; Løve US; Andersen PV; Kolbro T; Thorlacius-Ussing O; Monti A; Gögenur M; Kildsig J; Bondeven P; Schlesinger NH; Iversen LH; Gotschalck KA; Andersen CL
Ann Oncol; 2024 Feb; 35(2):229-239. PubMed ID: 37992872
[TBL] [Abstract][Full Text] [Related]
37. Early Circulating Tumor DNA Dynamics Predict Neoadjuvant Therapy Response and Recurrence in Colorectal Liver Metastases: A Prospective Study.
Wang XY; Zhang R; Han JH; Chen SQ; Zhao FL; Chen H; Lin J; Fan J; Zhu WW; Lu L; Chen JH
Ann Surg Oncol; 2023 Aug; 30(8):5252-5263. PubMed ID: 37202570
[TBL] [Abstract][Full Text] [Related]
38. Circulating tumor DNA for prognosis assessment and postoperative management after curative-intent resection of colorectal liver metastases.
Reinert T; Petersen LMS; Henriksen TV; Larsen MØ; Rasmussen MH; Johansen AFB; Øgaard N; Knudsen M; Nordentoft I; Vang S; Krag SRP; Knudsen AR; Mortensen FV; Andersen CL
Int J Cancer; 2022 May; 150(9):1537-1548. PubMed ID: 34994972
[TBL] [Abstract][Full Text] [Related]
39. Prophylactic liver transplantation for high-risk recurrent hepatocellular carcinoma.
Yang PC; Ho CM; Hu RH; Ho MC; Wu YM; Lee PH
World J Hepatol; 2016 Nov; 8(31):1309-1317. PubMed ID: 27872682
[TBL] [Abstract][Full Text] [Related]
40. Clinical utility of comprehensive circulating tumor DNA genotyping compared with standard of care tissue testing in patients with newly diagnosed metastatic colorectal cancer.
Benavides M; Alcaide-Garcia J; Torres E; Gil-Calle S; Sevilla I; Wolman R; Durán G; Álvarez M; Reyna-Fortes C; Ales I; Pereda T; Robles M; Kushnir M; Odegaard J; Faull I; Alba E
ESMO Open; 2022 Jun; 7(3):100481. PubMed ID: 35525184
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]